Dr Linn Baal » Blogg

68 – an important number for the Topotarget investor

Dr Linn Baal 2011-11-19 21:16
On yesterdays telephone conference it was asked what the target number of events is for the ongoing CUP trial and the answer from the CEO was 68. A model based on expressing progression free survival (PFS) as a exponential decay function yielded values of PFS for the BelCaP combination to at least 13 months provided median PFS for CaP is 6.0 months, implying an increase of >100%. This contrasts strongly to the primary endpoint set to +60% and yields the intriguing question of whether this study may serve as a basis for registration. UPDATED 31 JAN 2012 END OF BLOG4

Topotarget – Belinostat will be used off-label for CUP in the US

Dr Linn Baal 2011-03-22 11:51
The opinion of the principal investigators in the ongoing phase II CUP study is that good data for this study will trigger off-label use in the US for this indication provided that belinostat gets approved for PTCL. Sales is expected to contribute to the cash-flow from 2013 and onwards.

TopoTarget - Deleted Q1 Target Price

Dr Linn Baal 2011-02-11 10:11
In the recent analysis “TopoTarget - High Time to Double”, the target price was set to 7.5 DKr for the end of Q1 which was partly due to the belief that information regarding the ongoing PTCL study would be released. A few days ago, I submitted ...2